These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 24832097)

  • 1. Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study.
    Rahman M; Yang W; Akkina S; Alper A; Anderson AH; Appel LJ; He J; Raj DS; Schelling J; Strauss L; Teal V; Rader DJ;
    Clin J Am Soc Nephrol; 2014 Jul; 9(7):1190-8. PubMed ID: 24832097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD.
    Lamprea-Montealegre JA; Staplin N; Herrington WG; Haynes R; Emberson J; Baigent C; de Boer IH;
    Clin J Am Soc Nephrol; 2020 Jan; 15(1):47-60. PubMed ID: 31831577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD.
    Bajaj A; Xie D; Cedillo-Couvert E; Charleston J; Chen J; Deo R; Feldman HI; Go AS; He J; Horwitz E; Kallem R; Rahman M; Weir MR; Anderson AH; Rader DJ;
    Am J Kidney Dis; 2019 Jun; 73(6):827-836. PubMed ID: 30686529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Change in Dyslipidemia with Declining Glomerular Filtration Rate and Increasing Proteinuria in Children with CKD.
    Saland JM; Kupferman JC; Pierce CB; Flynn JT; Mitsnefes MM; Warady BA; Furth SL
    Clin J Am Soc Nephrol; 2019 Dec; 14(12):1711-1718. PubMed ID: 31712386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial.
    Kimura G; Kasahara M; Ueshima K; Tanaka S; Yasuno S; Fujimoto A; Sato T; Imamoto M; Kosugi S; Nakao K
    Clin Exp Nephrol; 2017 Jun; 21(3):417-424. PubMed ID: 27392909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LDL-C/apoB and HDL-C/apoA-1 ratios predict incident chronic kidney disease in a large apparently healthy cohort.
    Bae JC; Han JM; Kwon S; Jee JH; Yu TY; Lee MK; Kim JH
    Atherosclerosis; 2016 Aug; 251():170-176. PubMed ID: 27341533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbamylated Lipoproteins and Progression of Diabetic Kidney Disease.
    Tan KCB; Cheung CL; Lee ACH; Lam JKY; Wong Y; Shiu SWM
    Clin J Am Soc Nephrol; 2020 Mar; 15(3):359-366. PubMed ID: 32075807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function.
    Lash JP; Go AS; Appel LJ; He J; Ojo A; Rahman M; Townsend RR; Xie D; Cifelli D; Cohan J; Fink JC; Fischer MJ; Gadegbeku C; Hamm LL; Kusek JW; Landis JR; Narva A; Robinson N; Teal V; Feldman HI;
    Clin J Am Soc Nephrol; 2009 Aug; 4(8):1302-11. PubMed ID: 19541818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid profiles and risk of major adverse cardiovascular events in CKD and diabetes: A nationwide population-based study.
    Lee Y; Park S; Lee S; Kim Y; Kang MW; Cho S; Park S; Han K; Kim YC; Han SS; Lee H; Lee JP; Joo KW; Lim CS; Kim YS; Kim DK
    PLoS One; 2020; 15(4):e0231328. PubMed ID: 32271842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of kidney disease outcomes with risk factors for CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) study.
    Yang W; Xie D; Anderson AH; Joffe MM; Greene T; Teal V; Hsu CY; Fink JC; He J; Lash JP; Ojo A; Rahman M; Nessel L; Kusek JW; Feldman HI;
    Am J Kidney Dis; 2014 Feb; 63(2):236-43. PubMed ID: 24182662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients.
    Bermudez-Lopez M; Forne C; Amigo N; Bozic M; Arroyo D; Bretones T; Alonso N; Cambray S; Del Pino MD; Mauricio D; Gorriz JL; Fernandez E; Valdivielso JM
    Expert Opin Ther Targets; 2019 Jul; 23(7):619-630. PubMed ID: 31100024
    [No Abstract]   [Full Text] [Related]  

  • 12. Statins for treatment of dyslipidemia in chronic kidney disease.
    Shurraw S; Tonelli M
    Perit Dial Int; 2006; 26(5):523-39. PubMed ID: 16973506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The gender features of disorders of composition of lipids of blood serum in patients with chronic pathology of kidneys.].
    Murkamilov IT; Aytabaiev KA; Fomin VV; Murkamilova ZA; Rayimjanov ZR; Redjapova NA; Yusupov FA; Aydarov ZA
    Klin Lab Diagn; 2018; 63(3):152-158. PubMed ID: 30673194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid- lowering component of ALLHAT.
    Rahman M; Baimbridge C; Davis BR; Barzilay JI; Basile JN; Henriquez MA; Huml A; Kopyt N; Louis GT; Pressel SL; Rosendorff C; Sastrasinh S; Stanford C;
    Clin Nephrol; 2013 Oct; 80(4):235-48. PubMed ID: 23816477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated serum anion gap in adults with moderate chronic kidney disease increases risk for progression to end-stage renal disease.
    Banerjee T; Crews DC; Wesson DE; McCulloch CE; Johansen KL; Saydah S; Rios Burrows N; Saran R; Gillespie B; Bragg-Gresham J; Powe NR
    Am J Physiol Renal Physiol; 2019 Jun; 316(6):F1244-F1253. PubMed ID: 30908932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of pediatric CKD of nonglomerular origin in the CKiD cohort.
    Fathallah-Shaykh SA; Flynn JT; Pierce CB; Abraham AG; Blydt-Hansen TD; Massengill SF; Moxey-Mims MM; Warady BA; Furth SL; Wong CS
    Clin J Am Soc Nephrol; 2015 Apr; 10(4):571-7. PubMed ID: 25635034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute effects of fructose consumption on uric acid and plasma lipids in patients with impaired renal function.
    Zawiasa A; Nowicki M
    Metabolism; 2013 Oct; 62(10):1462-9. PubMed ID: 23866980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low HDL cholesterol as a predictor of chronic kidney disease progression: a cross-classification approach and matched cohort analysis.
    Kawachi K; Kataoka H; Manabe S; Mochizuki T; Nitta K
    Heart Vessels; 2019 Sep; 34(9):1440-1455. PubMed ID: 30874893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study.
    Dobre M; Yang W; Chen J; Drawz P; Hamm LL; Horwitz E; Hostetter T; Jaar B; Lora CM; Nessel L; Ojo A; Scialla J; Steigerwalt S; Teal V; Wolf M; Rahman M;
    Am J Kidney Dis; 2013 Oct; 62(4):670-8. PubMed ID: 23489677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDL Cholesterol, LDL Cholesterol, and Triglycerides as Risk Factors for CKD: A Mendelian Randomization Study.
    Lanktree MB; Thériault S; Walsh M; Paré G
    Am J Kidney Dis; 2018 Feb; 71(2):166-172. PubMed ID: 28754456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.